Notably, the treatments were virtually identical in preventing GVHD and significantly superior compared with untreated mice, as assessed by survival, GVHD clinical score, colon length, splenic CD4+ and CD8+ naive/effector cells, and thymic T cells (Supplemental Figure 4, A–D). The gene discussed is CD8A; the disease is graft versus host disease.